Oncotarget

Research Papers:

Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis

Matthias Christgen, Jana L. van Luttikhuizen, Mieke Raap, Peter Braubach, Lars Schmidt, Danny Jonigk, Friedrich Feuerhake, Ulrich Lehmann, Brigitte Schlegelberger, Hans H. Kreipe and Doris Steinemann _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:82733-82740. https://doi.org/10.18632/oncotarget.12421

Metrics: PDF 863 views  |   HTML 1036 views  |   ?  


Abstract

Matthias Christgen1, Jana L. van Luttikhuizen2, Mieke Raap1, Peter Braubach1, Lars Schmidt1, Danny Jonigk1, Friedrich Feuerhake1, Ulrich Lehmann1, Brigitte Schlegelberger2, Hans H. Kreipe1, Doris Steinemann2

1Institute of Pathology, Hannover Medical School, Hannover, Germany

2Institute of Human Genetics, Hannover Medical School, Hannover, Germany

Correspondence to:

Doris Steinemann, email: Steinemann.Doris@MH-Hannover.de

Keywords: HER2/ERBB2, OncoScan, breast cancer, copy number profiling, next generation sequencing

Received: July 02, 2016    Accepted: September 19, 2016    Published: October 03, 2016

ABSTRACT

HER2/ERBB2 amplification/overexpression determines the eligibility of breast cancer patients to HER2-targeted therapy. This study evaluates the agreement between ERBB2 copy number assessment by fluorescence in situ hybridization, a standard method recommended by the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP), and newly available DNA extraction-based methods. A series of n=29 formalin-fixed paraffin-embedded breast cancers were subjected to ERBB2 copy number assessment by fluorescence in situ hybridization (FISH, Vysis, Abbott). Following macrodissection of invasive breast cancer tissue and DNA extraction, ERBB2 copy number was also determined by molecular inversion probe array analysis (MIP, OncoScan, Affymetrix) and next generation sequencing combined with normalized amplicon coverage analysis (NGS/NAC, AmpliSeq, Ion Torrent). ERBB2 copy number values obtained by MIP or NGS/NAC were tightly correlated with ERBB2 copy number values obtained by conventional FISH (rs = 0.940 and rs = 0.894, P < 0.001). Using ASCO/CAP guideline-conform thresholds for categorization of breast cancers as HER2-negative, equivocal or positive, nearly perfect concordance was observed for HER2 classification by FISH and MIP (93% concordant classifications, κ = 0.87). Substantial concordance was observed for FISH and NGS/NAC (83% concordant classifications, κ = 0.62). In conclusion, MIP facilitates precise ERBB2 copy number detection and should be considered as an ancillary method for clinical HER2 testing.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12421